In this article, we will discuss about Enzulutamide (Dosage Overview). So, let’s get started.
Enzulutamide (XTANDI®) is indicated for the treatment of patients with:
• castration-resistant prostate cancer (CRPC)
• metastatic castration-sensitive prostate cancer (mCSPC).
The recommended dose of Enzulutamide (XTANDI®) is 160 mg (four 40 mg capsules) administered orally once daily. Enzulutamide (XTANDI®) can be taken with or without food.
If a patient experiences a ≥Grade 3 toxicity or an intolerable side effect, withhold dosing for one week or until symptoms improve to ≤ Grade 2, then resume at the same or a reduced dose (120 mg or 80 mg), if warranted.
Concomitant Strong CYP2C8 Inhibitors
The concomitant use of strong CYP2C8 inhibitors should be avoided if possible. If patients must be co-administered a strong CYP2C8 inhibitor, reduce the Enzulutamide (XTANDI®) dose to 80 mg once daily. If co-administration of the strong inhibitor is discontinued, the Enzulutamide (XTANDI®) dose should be returned to the dose used prior to initiation of the strong CYP2C8 inhibitor.
Concomitant Strong CYP3A4 Inducers
The concomitant use of strong CYP3A4 inducers should be avoided if possible. If patients must be co-administered a strong CYP3A4 inducer, increase the Enzulutamide (XTANDI®) dose from 160 mg to 240 mg once daily. If co-administration of the strong CYP3A4 inducer is discontinued, the Enzulutamide (XTANDI®) dose should be returned to the dose used prior to initiation of the strong CYP3A4 inducer.
The most common adverse reactions & 10%) that occurred more frequently
≥ 2% over placebo) in the Enzulutamide (XTANDI®)-treated patients are asthenia, fatigue, back pain, hot flush, constipation, arthralgia, decreased appetite. diarrhea, and hypertension.